Pay in 4 interest-free payments of $5.33 Learn more
Ships within 48 hours · Estimated delivery Jul 31 - Aug 5
is a Canadian company dedicated to the Canadian market and a long time partner with Felix
#PharmaNews #PharmaResults #EarningsUpdate #IndianPharma #PharmaUpdates #Harshal #PharmawithHJ #HJ Gland Pharma FY25 Results: Strong Margins, 31 Product Launches Gland Pharma Limited FY25 Results: Margins Hold Strong, Strategy Gathers Steam Financial Highlights: - FY25 Revenue: 5,617 Cr (1% YoY) - EBITDA Margin: 1,269 Cr (5% YoY) | Margin 23% - PAT: 698 Cr (10% YoY) | Margin at 12% - Dividend: 18/share final dividend recommended Business Highlights: - 31 product launches in FY25, including new molecules like Latanoprost & Dexamethasone - 32 ANDA approvals, 24 filings U.S
MRIs, X-rays, CT scans, and bone scans can aid in locating a tumor and/or possible metastasis
BPC-157 was classified as FDA Category 2 in 2023 and cannot be compounded by US pharmacies
US$ 28.29
US$ 26.00
US$ 25.03
US$ 21.31
